MedImmune's bispecific mAb for Pseudomonas-related ocular keratitis

INDICATION: Pseudomonas

Mouse studies suggest MEDI3902, a bispecific mAb against P. aeruginosa Psl and PcrV, could help treat ocular keratitis caused by P. aeruginosa infection. In a mouse model of bacterial keratitis with ocular P. aeruginosa infection, MEDI3902 decreased the size of biofilm on the cornea, ocular bacterial loads, eye opacity and clinical disease scores compared with control IgG. Also in the model, MEDI3902 plus the standard of care antibiotic, tobramycin, decreased eye opacity and clinical scores compared with either agent alone. Next steps by the MedImmune LLC unit of AstraZeneca plc could include clinical testing of MEDI3902 for bacterial keratitis caused by P. aeruginosa...